GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Thiogenesis Therapeutics Corp (TSXV:TTI) » Definitions » FCF Yield %

Thiogenesis Therapeutics (TSXV:TTI) FCF Yield % : -13.53 (As of Jun. 25, 2024)


View and export this data going back to 2022. Start your Free Trial

What is Thiogenesis Therapeutics FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Thiogenesis Therapeutics's Trailing 12-Month Free Cash Flow is C$-4.37 Mil, and Market Cap is C$32.30 Mil. Therefore, Thiogenesis Therapeutics's FCF Yield % for today is -13.53%.

The historical rank and industry rank for Thiogenesis Therapeutics's FCF Yield % or its related term are showing as below:

TSXV:TTI' s FCF Yield % Range Over the Past 10 Years
Min: -14.78   Med: 0   Max: 0
Current: -13.53


TSXV:TTI's FCF Yield % is ranked better than
52.13% of 1548 companies
in the Biotechnology industry
Industry Median: -14.645 vs TSXV:TTI: -13.53

Thiogenesis Therapeutics's FCF Margin % for the quarter that ended in Mar. 2024 was 0.00%.


Thiogenesis Therapeutics FCF Yield % Historical Data

The historical data trend for Thiogenesis Therapeutics's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Thiogenesis Therapeutics FCF Yield % Chart

Thiogenesis Therapeutics Annual Data
Trend Dec19 Dec20 Feb21 Feb22 Dec23
FCF Yield %
- - - - -9.72

Thiogenesis Therapeutics Quarterly Data
Dec19 Sep20 Dec20 Sep21 Feb22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
FCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -16.08 -11.19 -13.09 -8.34 -22.50

Competitive Comparison of Thiogenesis Therapeutics's FCF Yield %

For the Biotechnology subindustry, Thiogenesis Therapeutics's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Thiogenesis Therapeutics's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Thiogenesis Therapeutics's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Thiogenesis Therapeutics's FCF Yield % falls into.



Thiogenesis Therapeutics FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Thiogenesis Therapeutics's FCF Yield % for the fiscal year that ended in Dec. 2023 is calculated as

FCF Yield %=Free Cash Flow / Market Cap
=-3.248 / 33.42795
=-9.72%

Thiogenesis Therapeutics's annualized FCF Yield % for the quarter that ended in Mar. 2024 is calculated as

FCF Yield %=Free Cash Flow * Annualized Factor / Market Cap
=-1.996 * 4 / 35.486568
=-22.50%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Thiogenesis Therapeutics FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


Thiogenesis Therapeutics FCF Yield % Related Terms

Thank you for viewing the detailed overview of Thiogenesis Therapeutics's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Thiogenesis Therapeutics (TSXV:TTI) Business Description

Traded in Other Exchanges
N/A
Address
4 King Street West, Suite 401, Toronto, ON, CAN, M5H 1B6
Thiogenesis Therapeutics Corp is a clinical stage biotech company. The Company is developing thiol-active therapeutic compounds, that are prodrugs, used to treat unmet pediatric medical needs. TTI-0102, the Company's lead compound, was developed to address the obstacles facing previous thiol-based drugs, their short half-live and side effects. TTI-0102's initial applications are for mitochondrial disease, Rett syndrome and pediatric NASH.
Executives
Vincent P. Stanton 10% Security Holder